18F-Fluciclovine Avid Axillary Lymph Nodes After COVID-19 Vaccination on PET/CT for Suspected Recurrence of Prostate Cancer.
Justin G PeacockElisabeth A BanksNathan E McWhorterPublished in: Journal of nuclear medicine technology (2021)
Abnormal increased FDG avidity of axillary lymph nodes has become a frequent diagnostic dilemma on PET/CT in the current climate of global vaccinations directed against SARS-CoV-2. This is due to the inflammatory response evoked by vaccines and the non-specific nature of F18-Fludeoxyglucose (FDG), which includes increased uptake in both malignant and inflammatory processes. Similarly, F18-Fluciclovine (Axumin), an amino acid analog indicated for the assessment of biochemical recurrence of prostate cancer, may also demonstrate non-specific inflammatory uptake. We report a case of 18F-Fluciclovine PET/CT obtained for concern of prostate cancer which demonstrated isolated avid lymph nodes in the left axilla. Screening questionnaire revealed that the patient had received the second dose of the Pfizer-BioNTech COVID-19 Vaccine in his left shoulder recently and hence the uptake was determined to be reactive.
Keyphrases
- pet ct
- lymph node
- prostate cancer
- sars cov
- sentinel lymph node
- radical prostatectomy
- inflammatory response
- coronavirus disease
- neoadjuvant chemotherapy
- positron emission tomography
- respiratory syndrome coronavirus
- amino acid
- oxidative stress
- climate change
- free survival
- pulmonary embolism
- lipopolysaccharide induced
- single cell
- immune response
- toll like receptor
- radiation therapy
- psychometric properties